In November 2025, the Red Crescent Medical Procurement Organization provided the vital drug Naglazyme for more than 30 patients suffering from the rare disease Mucopolysaccharidosis (MPS) and distributed it to 14 provinces across the country. The Organization is currently undertaking the necessary steps to procure and supply the medicine for patients during December as well.
According to the Public Relations and
International Affairs Unit of the Medical Procurement Organization, in line
with its commitment to supporting patients with rare and special conditions,
the Organization supplied Naglazyme in November 2025 for over 30 individuals
diagnosed with MPS and ensured its delivery to 14 provinces nationwide. The
process of procurement and distribution for December is also underway.
Mucopolysaccharidoses (MPS) are a group of
rare, progressive disorders caused by the deficiency or absence of specific
enzymes in the body. This deficiency leads to the abnormal accumulation of
complex sugar molecules (glycosaminoglycans) in cells and connective tissues,
resulting in severe damage to various organs. At present, approximately 100
individuals across Iran are affected by this condition and require continuous
treatment with Naglazyme.
The Red Crescent Medical Procurement
Organization, emphasizing the importance of public health, considers continuous
service provision and the reduction of concerns regarding medicines and medical
equipment as its core objectives. By ensuring the supply of essential
medicines, the Organization strives to provide greater reassurance and peace of
mind for patients and their families.